Companies / encarta.bio
encarta.bio
United States
En Carta Diagnostics develops a Lyme test that has received FDA Breakthrough Designation.
encarta.bio, based in United States, has 3 investors on file, among them CentraleSupélec Venture, Creative Destruction Lab and Ring Capital. Its latest round on record is Seed, 10 Jul 2026. Its site was last checked 12 Nov 2026: site answers.
Funding
1 round on recordRound sizes and total raised are on Fundup AI, our sister product for funding data.
Investors
3 investors on file| Investor | Evidence | Type |
|---|---|---|
| Page + round | Venture capital | |
| Portfolio page | Accelerator | |
| Portfolio page | Venture capital |
A company is shown only after its own site answers and carries its name. Sites are checked again on a schedule, because domains lapse and get bought. Round stages and dates come from Fundup AI; investor links come from portfolio pages and rounds; other facts name their source when you point at them. How we grade the data
Get encarta.bio and its investors as data
Look up any company's investors, or any investor's full portfolio, through one API key or MCP. A free account also opens Ask AI searches and alerts when CentraleSupélec Venture adds a company.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/companies/encarta.bio/investors
# also
GET /v1/companies/encarta.bio
GET /v1/companies/encarta.bio/news